Oncology Times - Ot Broadcasts From The Ipad Archives
Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue!
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:06:57
- Mas informaciones
Informações:
Sinopsis
Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer--analysis of results from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study reported at ECCO15-ESMO34.
